| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $5.7M | +4.8% | -15.7% |
| SG&A Expense | $8.6M | +24.7% | -45.3% |
| Net Income | -$9.2M | -40.9% | +56.9% |
| EPS (Basic) | -$0.18 | -38.5% | +68.4% |
| EPS (Diluted) | -$0.18 | -38.5% | +68.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $197.7M | -65.8% | +66.7% |
| Short-term Investments | $371.0M | — | — |
| Accounts Receivable | $250K | +189.4% | — |
| Current Assets | $571.7M | -1.6% | +378.5% |
| Total Assets | $603.9M | -0.4% | +335.0% |
| Current Liabilities | $6.0M | +37.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$9.3M | -131.9% | — |
| Capital Expenditures | $8.8M | — | — |
| Investing Cash Flow | -$380.5M | — | — |
| Financing Cash Flow | $384.2M | +0.7% | — |
| Free Cash Flow | -$18.0M | — | — |
| +36.0% |
| Total Liabilities | $8.0M | +23.9% | +18.2% |
| Stockholders' Equity | $595.9M | -0.6% | +351.3% |